<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867932</url>
  </required_header>
  <id_info>
    <org_study_id>M07-005</org_study_id>
    <nct_id>NCT00867932</nct_id>
  </id_info>
  <brief_title>Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects</brief_title>
  <official_title>An Open Label Multi Center Study of Eculizumab in Children and Adolescents With Diagnosis of Paroxysmal Nocturnal Hemoglobinuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine appropriate dose regimens of eculizumab in
      pediatric and/or adolescent patients with paroxysmal nocturnal hemoglobinuria (PNH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open label, multicenter study of eculizumab administered intravenously (IV) to
      approximately 6 to 8 pediatric and adolescent patients aged 2-17 years with PNH.

      Planned duration of treatment was 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 12, 2011</completion_date>
  <primary_completion_date type="Actual">May 12, 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum trough and peak concentrations of eculizumab</measure>
    <time_frame>Week 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum trough and peak concentrations of eculizumab</measure>
    <time_frame>Weeks 6 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Hemoglobinuria, Paroxysmal</condition>
  <arm_group>
    <arm_group_label>Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eculizumab administered intravenously for 12 weeks. Dosing regimen based on body weight as follows:
≥30 kg: induction/loading = 600 mg weekly x 4; maintenance = 900 mg Wk5; 900 mg Q2 wks 20 - &lt;30 kg: induction/loading = 600 mg weekly x 2; maintenance = 600 mg Wk3; 600 mg Q2 wks 10 - &lt;20 kg: induction/loading = 600 mg weekly x 1; maintenance = 300 mg Wk2; 300 mg Q2 wks 5 - &lt;10 kg: induction/loading = 300 mg weekly for 1 week; maintenance = 300 mg Wk2; 300 mg Q3 wks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <arm_group_label>Eculizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects between 2-17 years;

          -  Diagnosis of PNH;

          -  subjects with ≥ 5% glycosylphosphatidylinositol (GPI) deficient red blood cells or
             granulocytes as confirmed by flow cytometry;

          -  subjects must have shown evidence of hemolytic anemia as documented by lactate
             dehydrogenase (LDH) greater than the upper limit of normal or at least one transfusion
             in the past two years for anemia or anemia related symptoms;

          -  Written Informed Consent from parent/guardian;

          -  Negative pregnancy Test for Women of Child Bearing Potential;

          -  Sexually active females must document reliable and medically approved method of birth
             control;

          -  Patient must be vaccinated against N. meningitidis, S. Pneumoniae and H. Influenzae at
             least 14 days prior to to study drug initiation or receive antibiotics for 14 days
             after the vaccination;

        Exclusion Criteria:

          -  Prior eculizumab treatment;

          -  Presence or suspicion of active bacterial infection;

          -  Participation in another concurrent clinical trial;

          -  History of meningococcal/pneumococcal/gonococcal disease;

          -  Pregnant, breast feeding or intending to conceive during study including the safety
             follow up visits;

          -  Any other condition that could increase the patients risk or confound the outcome of
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camille Bedrosian, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alexion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>LA</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <disposition_first_submitted>March 9, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 9, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 10, 2017</disposition_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paroxysmal Nocturnal Hemoglobinuria (PNH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

